- GMP center certified for specific cell processing material manufacturing… Building a local 바카라 토토 cell production hub
- Plan to provide atopic dermatitis treatment using umbilical cord blood 바카라 토토 cells under review in Japan
[by Yoo, Ha Eun] Kangstem Biotech announced on February 19 that it has received approval from the Japanese Ministry of Health, Labor, and Welfare for its ‘Type 2 바카라 토토 Medicine Provision Plan’ using adipose stem cells. The company aims to launch its business within the first quarter, supplying Japanese medical institutions with adipose stem cells derived from the adipose tissue of chronic pain patients through separation and incubation processes.
In Japan, 바카라 토토 medicine is largely categorized into three risk levels, with Type 2 representing a medium-risk classification. This group includes autologous stem cells, somatic cells, cultured cells, and non-homologous medical technologies.
In 2024, Kangstem Biotech established the groundwork for stem cell production at Japanese 바카라 토토 medicine institutions by obtaining approval from the domestic Good Manufacturing Practice (GMP) Center for the manufacture of specific cell-processed products. With the final approval of the Type 2 바카라 토토 Medicine Provision Plan, the company explains that it has now completed all necessary preparations to launch its 바카라 토토 medicine business in Japan.
Kangstem Biotech is currently coordinating with medical institutions in Tokyo, Osaka, and other regions in Japan to confirm patient treatment plans and schedules, aiming to administer the treatment within the first quarter of this year. With this approval, the company seeks to establish mid- to long-term revenue streams while expanding the application of 바카라 토토 treatments to high-demand conditions such as aging and osteoarthritis.
In addition, the company aims to penetrate the Japanese 바카라 토토 medicine market and provide patient treatments using 'SELAF', its proprietary high-quality stem cell technology. This platform features advanced methods for isolating and cultivating stem cells found in extremely small quantities, along with an incubation medium technology that ensures high proliferation capacity and consistent cell quality.
Japan’s 바카라 토토 medicine market is projected to grow from JPY 290 billion (approximately USD 1.9 billion) in 2025 to JPY 910 billion (approximately USD 5.9 billion) by 2040. Notably, chronic pain diseases account for a substantial share of stem cell-based 바카라 토토 treatments, representing approximately 25.8% of the market, according to the data from the Japanese Society for 바카라 토토 Medicine. Given the high demand, strong patient interest and steady sales growth are anticipated.
Furthermore, Kangstem Biotech has secured approval from the Specific Recognition 바카라 토토 Medicine Committee for its Type 1 바카라 토토 Medicine Provision Plan, which focuses on treating atopic dermatitis using umbilical cord blood stem cells. The plan is currently under review by the Japanese Ministry of Health, Labor, and Welfare, and upon approval, the company’s treatment, 'Furestem-AD Injection,' will be immediately available to patients as an atopic dermatitis treatment.